Recursion Pharmaceuticals, Inc. remains a Sell as pipeline progress, notably REC-4881 in FAP, fails to surpass cheap alternatives like Celebrex. REC-4881's Phase 1/2 data show a median polyp reduction ...
Abstract: This paper presents a data-driven adaptive steady state-integral-derivative (SS-ID) control algorithm that uses gradient descent and recursive least squares (RLS) with a forgetting factor. A ...
Dec 8 (Reuters) - Recursion Pharma (RXRX.O), opens new tab, which uses artificial intelligence to discover new drug candidates, said on Monday its experimental oral drug helped reduce abnormal growths ...
In early December 2025, Recursion Pharmaceuticals released clinical data from the TUPELO Phase 1b/2 trial of REC-4881, providing fresh insight into the candidate’s safety and efficacy profile. This ...
A study of recursive least squares (RLS) adaptive filter algorithm in noise removal from ECG signals
Abstract: Electrocardiogram (ECG) is a diagnostic procedure that measures and records the electrical activity of heart in detail. By reviewing an ECG report, one's condition of heart can be evaluated.
After twelve years at the helm of AI-drug developer Recursion, Chris Gibson will hand the CEO baton to Najat Khan, PhD, the company’s chief R&D officer and chief commercial officer, effective January ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback